European drug launches drop 35 percent amid US pressure
Drugmakers are slowing European launches to protect US prices under new federal rules. Data shows a 35 percent drop in EU entries as firms seek clarity.
Xurve View
Insights:
Xurve View
Pharmaceutical companies are increasingly delaying the introduction of new medicines in Europe as they navigate the ripple effects of pricing policies in the United States. The shift follows efforts by the Trump administration to link domestic drug prices to those paid in other developed nations, a strategy known as most-favored-nation pricing.
